IL218999A - Combination containing n - {3 - [5 - (2 - amino - 4 - pyrimidinyl) - 2 - (1,1 - dimethylethyl) - 1,3 - thiazole - 4 - ram] - 2 - fluorophenyl} - 2,6 - Difluorobenzensulfonamide and n - {(1s) –2– Amino –1 - [(3,4-Difluorophenyl) methyl] Ethyl-5-Chloro-4– (4-Chloro-1-Methyl-1H-Pyrazole-5-Il 2) - 2-Fornucarboxamide for Cancer Treatment - Google Patents

Combination containing n - {3 - [5 - (2 - amino - 4 - pyrimidinyl) - 2 - (1,1 - dimethylethyl) - 1,3 - thiazole - 4 - ram] - 2 - fluorophenyl} - 2,6 - Difluorobenzensulfonamide and n - {(1s) –2– Amino –1 - [(3,4-Difluorophenyl) methyl] Ethyl-5-Chloro-4– (4-Chloro-1-Methyl-1H-Pyrazole-5-Il 2) - 2-Fornucarboxamide for Cancer Treatment

Info

Publication number
IL218999A
IL218999A IL218999A IL21899912A IL218999A IL 218999 A IL218999 A IL 218999A IL 218999 A IL218999 A IL 218999A IL 21899912 A IL21899912 A IL 21899912A IL 218999 A IL218999 A IL 218999A
Authority
IL
Israel
Prior art keywords
chloro
amino
methyl
difluorobenzenesulfonamide
furancarboxamide
Prior art date
Application number
IL218999A
Other languages
English (en)
Hebrew (he)
Other versions
IL218999A0 (en
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL218999A0 publication Critical patent/IL218999A0/en
Publication of IL218999A publication Critical patent/IL218999A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL218999A 2009-10-08 2012-04-02 Combination containing n - {3 - [5 - (2 - amino - 4 - pyrimidinyl) - 2 - (1,1 - dimethylethyl) - 1,3 - thiazole - 4 - ram] - 2 - fluorophenyl} - 2,6 - Difluorobenzensulfonamide and n - {(1s) –2– Amino –1 - [(3,4-Difluorophenyl) methyl] Ethyl-5-Chloro-4– (4-Chloro-1-Methyl-1H-Pyrazole-5-Il 2) - 2-Fornucarboxamide for Cancer Treatment IL218999A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24980309P 2009-10-08 2009-10-08
PCT/US2010/051907 WO2011044414A1 (en) 2009-10-08 2010-10-08 Combination

Publications (2)

Publication Number Publication Date
IL218999A0 IL218999A0 (en) 2012-06-28
IL218999A true IL218999A (en) 2015-08-31

Family

ID=43857162

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218999A IL218999A (en) 2009-10-08 2012-04-02 Combination containing n - {3 - [5 - (2 - amino - 4 - pyrimidinyl) - 2 - (1,1 - dimethylethyl) - 1,3 - thiazole - 4 - ram] - 2 - fluorophenyl} - 2,6 - Difluorobenzensulfonamide and n - {(1s) –2– Amino –1 - [(3,4-Difluorophenyl) methyl] Ethyl-5-Chloro-4– (4-Chloro-1-Methyl-1H-Pyrazole-5-Il 2) - 2-Fornucarboxamide for Cancer Treatment

Country Status (16)

Country Link
US (2) US8835450B2 (enExample)
EP (1) EP2485593B1 (enExample)
JP (1) JP2013507382A (enExample)
KR (1) KR20120100978A (enExample)
CN (1) CN102665418B (enExample)
AU (1) AU2010303363B2 (enExample)
BR (1) BR112012008271A2 (enExample)
CA (1) CA2777085A1 (enExample)
EA (1) EA022982B1 (enExample)
ES (1) ES2532026T3 (enExample)
IL (1) IL218999A (enExample)
MX (1) MX2012004139A (enExample)
PL (1) PL2485593T3 (enExample)
PT (1) PT2485593E (enExample)
WO (1) WO2011044414A1 (enExample)
ZA (1) ZA201202494B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302275A (zh) * 2012-04-24 2015-01-21 葛兰素史密斯克莱知识产权（第2号）有限公司 类固醇反应性皮肤病的治疗方法
AU2013334945A1 (en) * 2012-10-22 2015-04-23 Novartis Ag Combination
BR112015008924A2 (pt) * 2012-10-22 2017-07-04 Glaxosmithkline Llc combinação
CN104109159A (zh) 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309205T1 (de) * 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
IL149150A0 (en) * 1999-11-22 2002-12-01 Smithkline Beecham Plc 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
WO2004080972A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
EP1981884B1 (en) * 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
EA201270526A1 (ru) 2012-12-28
CN102665418A (zh) 2012-09-12
JP2013507382A (ja) 2013-03-04
WO2011044414A1 (en) 2011-04-14
CN102665418B (zh) 2014-10-29
EP2485593B1 (en) 2015-01-07
IL218999A0 (en) 2012-06-28
PL2485593T3 (pl) 2015-06-30
US8835450B2 (en) 2014-09-16
AU2010303363A1 (en) 2012-04-26
US9402846B2 (en) 2016-08-02
BR112012008271A2 (pt) 2015-09-22
AU2010303363B2 (en) 2013-09-05
MX2012004139A (es) 2012-09-07
US20120196886A1 (en) 2012-08-02
KR20120100978A (ko) 2012-09-12
EP2485593A4 (en) 2013-02-13
ZA201202494B (en) 2012-12-27
EP2485593A1 (en) 2012-08-15
CA2777085A1 (en) 2011-04-14
PT2485593E (pt) 2015-04-28
ES2532026T3 (es) 2015-03-23
EA022982B1 (ru) 2016-04-29
US20140350039A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
IL321827A (en) Combinations of trastuzumab-mcc-dm1 and 5-fu for use in the treatment of ERBB2-expressing cancers
EP2320904A4 (en) AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
IL218999A (en) Combination containing n - {3 - [5 - (2 - amino - 4 - pyrimidinyl) - 2 - (1,1 - dimethylethyl) - 1,3 - thiazole - 4 - ram] - 2 - fluorophenyl} - 2,6 - Difluorobenzensulfonamide and n - {(1s) –2– Amino –1 - [(3,4-Difluorophenyl) methyl] Ethyl-5-Chloro-4– (4-Chloro-1-Methyl-1H-Pyrazole-5-Il 2) - 2-Fornucarboxamide for Cancer Treatment
IL220212A (en) Derivatives 5 - [(2-Aminopyrimide-4-Yl) Methylidan] -3,1-Thiazolidine-4,2-Discussion and Pharmaceutical Preparations Containing Them
ZA201007918B (en) Phenyl and benzodioxinyl substituted indazoles derivatives
SI2947072T1 (sl) 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
EP2324029A4 (en) HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT
EP2250575A4 (en) DATA ENHANCEMENT AND STORAGE FOR RECALL AND USE
EP2381852A4 (en) APICAL ANCHORAGE OF THE PAPILLARY MUSCLES FOR REDUCTION OF THE LEFT VENTRICLE
GB0818175D0 (en) Alkoxy compounds for disease treatment
AP2011005646A0 (en) Use of dithiin tetracarboximides for treating phytopathogenic fungi.
GB201108711D0 (en) Secure document managment
EP2440757A4 (en) Integrated pump and injector for exhaust after treatment
ZA200900505B (en) N-(Aminoheteroaryl)-1 H-Indole-2-Carboxamide derivatives, and preparation and thepateutic application thereof
PL2475368T3 (pl) N-(4-((3-(2-amino-4-pirymidynylo)-2-pirydynylo)oksy)fenylo)-4-(4-metylo-2-tienylo)-1-ftalazynoamina do stosowania w leczeniu raka opornego na czynniki antymitotyczne
GB2460099B (en) Detachable pouch device for loading human tissue
IL234405A (en) N [5 - (aminosulfonyl) -4-methyl-3,1-thiazole-2-ram] - n - methyl 2 - [4 - (2-pyridinyl) phenyl] monohydrate acetylamide
IL218321A (en) Medication for the treatment and / or prevention of mood disorders containing n- (4- (2-furyl) -5- (tetrahydrofuran-4-carbonyl) thiazole-2-yl) -6-methylpyridine-3-carboxamide
PL2370070T3 (pl) Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów
EP2300018A4 (en) PAEONIFLORINE PREPARATIONS AND THEIR USE OF FAT REDUCTION
ZA200908394B (en) Raccoon poxvirus expressing genes of porcine virus
PT2104497E (pt) Derivados de ureia e sulfamida enquanto inibidores de tafia
IL219000A (en) Combination of n - - {3 - [5 - (2-amino-4-pyrimidinyl) -2- (1,1-dimethylethyl) -1,3-thiazole-4-yl] -2-fluorophenyl} -2,6 -Defluorobenzenesulfonamide or its acceptable pharmacy salt, and n - {(1s) –2– amino-1 - [(3-fluorophenyl) methyl] ethyl} –5 chloro – 4 (4-chloro – 1 – methyl – 1 h –pyrazole– 5-ram) -2-thiophenecarboxamide hydrochloride and its use in the preparation of a cancer drug
GB201103991D0 (en) Vessel for contagious fish disease control
EP2388240A4 (en) HYDRAULIC CEMENT COMPRISING ORGANIC SILICON NANOPARTICLES

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees